Capricor CAPR Surges as Cantor Flips Bullish on Deramiocel FDA Path
Capricor Therapeutics' CAPR stock is spiking in premarket trading after Cantor Fitzgerald upgraded the stock to Overweight with a $28 target, citing the potential for a narrower Deramiocel indication aided by a 24-month HOPE-3 BLA extension. The FDA decision is expected by August 22. Capricor plans to amend its BLA for Deramiocel, while all other pipeline work remains on hold. The company posted a Q2 loss of $0.70 per share and held about $237.9 million in cash, with Cantor projecting up to 278% upside from current levels.